Oppenheimer & Co. Inc. lessened its holdings in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 11.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,306 shares of the medical technology company’s stock after selling 1,303 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Hill-Rom were worth $1,085,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in HRC. Litman Gregory Asset Management LLC bought a new position in Hill-Rom in the second quarter worth $26,000. Tortoise Investment Management LLC bought a new position in Hill-Rom in the second quarter worth $31,000. TRUE Private Wealth Advisors bought a new position in Hill-Rom in the second quarter worth $38,000. AllSquare Wealth Management LLC bought a new position in Hill-Rom in the second quarter worth $44,000. Finally, CENTRAL TRUST Co raised its holdings in Hill-Rom by 251.9% in the third quarter. CENTRAL TRUST Co now owns 475 shares of the medical technology company’s stock worth $50,000 after purchasing an additional 340 shares in the last quarter. Institutional investors own 82.61% of the company’s stock.
A number of equities analysts have issued reports on the company. ValuEngine downgraded Hill-Rom from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Morgan Stanley increased their price objective on Hill-Rom from $108.00 to $113.00 and gave the stock an “equal weight” rating in a report on Monday. KeyCorp increased their price objective on Hill-Rom from $114.00 to $125.00 and gave the stock an “overweight” rating in a report on Monday, August 5th. Needham & Company LLC reissued a “buy” rating and issued a $125.00 target price on shares of Hill-Rom in a research note on Tuesday, August 6th. Finally, UBS Group increased their target price on Hill-Rom from $122.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Hill-Rom has an average rating of “Buy” and a consensus target price of $118.67.
Hill-Rom (NYSE:HRC) last released its earnings results on Friday, November 1st. The medical technology company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.65 by $0.04. Hill-Rom had a return on equity of 21.67% and a net margin of 5.24%. The firm had revenue of $782.80 million for the quarter, compared to analysts’ expectations of $759.14 million. During the same period in the prior year, the firm posted $1.63 earnings per share. The company’s quarterly revenue was up 3.1% on a year-over-year basis. As a group, analysts forecast that Hill-Rom Holdings, Inc. will post 5.52 earnings per share for the current fiscal year.
In related news, SVP Paul Sherwood Johnson sold 6,470 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $104.26, for a total transaction of $674,562.20. Following the sale, the senior vice president now directly owns 8,215 shares of the company’s stock, valued at $856,495.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.73% of the company’s stock.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Read More: Cost of Capital Explained
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.